GlassScriptPhysician profile
Adrienne Rencic
NPI 1295726891
$5,996.32
in general payments reported to CMS, 2019-2025
26 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $474 · 2021: $264 · 2022: $987 · 2023: $3,100 · 2024: $892 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,833 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,833.48 |
| Education | $273.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,295.17 | 2021-2024 | Tremfya, Simponi Aria, Simponi |
| Dermavant Sciences, INC. | $647.01 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $566.85 | 2020-2024 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $455.43 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $445.38 | 2019-2023 | Dupixent |
| Galderma Laboratories, L.P. | $375.34 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $346.61 | 2020-2023 | Otezla |
| Incyte Corporation | $329.47 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $290.63 | 2020-2024 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $238.31 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $162.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $151.42 | 2019-2024 | |
| Genzyme Corporation | $144.49 | 2019-2024 | |
| Leo Pharma INC. | $117.75 | 2021-2024 | Adbry |
| Janssen Scientific Affairs, LLC | $96.43 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $44.63 | 2019 | |
| Genentech USA, INC. | $42.21 | 2023-2024 | Erivedge |
| Takeda Pharmaceuticals U.S.A., INC. | $42.16 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.52 | 2022-2024 | Cabtreo |
| Pfizer INC. | $34.14 | 2021-2024 | |
| Ucb, INC. | $26.86 | 2023 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.76 | 2024 | Spevigo |
| Krystal Biotech INC | $25.37 | 2023 | Vyjuvek |
| Celgene Corporation | $24.38 | 2019 | |
| Almirall LLC | $23.41 | 2022 | |
| Biofrontera INC. | $9.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Rencic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.